Bayer’s Two-Front Offensive: Legal Closure Paves the Way for a Pipeline-Fueled Rebound

The Supreme Court’s 7–2 ruling excising thousands of Roundup claims from Bayer’s docket was the kind of event that sends a stock rocketing 23% in a week. And it did. But the rally to €46.54 also masks a deeper story: the Leverkusen-based group is using that hard-won breathing room to reshape its entire pharmaceutical future — through acquisitions, AI-driven discovery, and a high-stakes FDA decision on a stroke drug.

The Asundexian verdict arrives at a critical moment

With Xarelto patents crumbling and revenues from that blockbuster plunging by a third to $2.6 billion in 2025, Bayer’s most immediate pipeline need is Asundexian, an oral Factor XIa inhibitor designed for stroke prevention. The drug has already cleared several regulatory hurdles: the FDA accepted the application in May 2026 and granted priority review based on the pivotal OCEANIC-STROKE study; China followed with priority review of its own. The European Medicines Agency has been reviewing the submission since June — the first-ever European filing for a drug in this class.

The market opportunity is substantial. Stroke ranks as the second-leading cause of death in Europe, with roughly ten million people living with its effects. Bayer currently holds a regulatory lead over rivals Bristol Myers Squibb and Johnson & Johnson, whose competing drug milvexian has yet to secure equivalent approval milestones.

A $2.45 billion ophthalmology bet

Days before the court news broke, Bayer quietly closed the acquisition of Perfuse Therapeutics, paying $300 million upfront with milestone payments that could total $2.45 billion. The prize is PER-001, an intravitreal implant in Phase II development for glaucoma and diabetic retinopathy — conditions affecting up to 80 million and 146 million people globally, respectively. Described as a potential first-in-class therapy, PER-001 is a small-molecule endothelin receptor antagonist implant with no direct comparator on the market.

The move adds a new therapeutic pillar alongside Bayer’s established franchises. Nubeqa and Kerendia continue to post strong revenue growth, while the FDA approved contrast agent AMBELVIST in June, adding to the commercial arsenal.

Artificial intelligence enters the lab

At the tail end of June, Bayer formalised a research collaboration with Iambic Therapeutics, a biotechnology company using its proprietary AI platforms Enchant and NeuralPLexer to identify novel drug targets and design molecules for difficult-to-reach biological structures. The partnership targets low-molecular-weight therapies against challenging disease targets — an area where traditional drug development routinely fails. Conventional discovery takes ten to fifteen years and costs roughly $2.6 billion per approved drug, with more than 90% of candidates falling by the wayside in clinical trials. The AI-driven approach aims to shrink optimisation cycles and fortify Bayer’s pipeline for the next decade.

Should investors sell immediately? Or is it worth buying Bayer?

Oncology also receives attention through the investigative WRN inhibitor VVD-214, developed with Vividion. The drug targets tumours with MSI-H or dMMR profiles and is being evaluated in patients with advanced colorectal cancer who have exhausted existing treatment options. Cell and gene therapies are expected to open new growth avenues starting early next decade.

Financial relief meets lingering burdens

The Supreme Court decision effectively closes a chapter that had cost Bayer more than $10 billion in settlement payments. The company had previously booked roughly €5 billion in legal payouts for 2026; that line item can now be largely written down. Net debt improved to €29.8 billion in 2025 from €32.6 billion a year earlier, while free cash flow stood at €2.1 billion.

Yet the balance sheet remains under pressure. Without the legal reprieve, Bayer had forecast cash outflows of about €5 billion for litigation in 2026, which would have pushed free cash flow negative. The ruling could change that trajectory, but the final judicial stamp on the broader glyphosate settlement is not expected until a hearing in Missouri on 9 July 2026.

Technicals flash a warning

After seven days of aggressive buying, the stock’s relative strength index sits at 80.5 — firmly in overbought territory. The share price now stands 27.55% above its 200-day moving average and just 6.79% below the 52-week high of €49.93 set in February.

That gap reflects the market’s sentiment shift rather than operational delivery. To sustain the current valuation, Bayer must demonstrate that its pipeline can generate genuine growth — starting with the FDA’s verdict on Asundexian. The legal overhang is largely gone. The real test of whether Bayer can transform itself back into a growth-oriented pharmaceuticals company is only just beginning.